RxDoctor Payments Data

Eric Mann, MD

Ophthalmology · Belleville, ILNPI 1841289014

Payments from drug & device makers

$3,555in general payments, 2019–2025

Across 116 payments — averaging $30.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$875
  • AbbVie$549
  • Novartis$465
  • Sun Pharmaceutical Industries Inc.$309
  • Oyster Point Pharma, Inc.$291
  • Thea Pharma Inc.$222
  • plus $845 from 11 others

What the payments were for

  • Travel & lodging$78022%
  • Food & beverage$2,70776%
  • Education$682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,555 in reported general payments places this provider in the 70th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,057,471
Medicare patients
728
Services billed
9,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine62$68,337
XiidraLifitegrast46$59,395
Cyclosporine36$26,773
LumiganBimatoprost35$15,783
CequaCyclosporine13$15,437
Prednisolone Acetate254$12,344
RocklatanNetarsudil Mesylat/Latanoprost21$11,711
Latanoprost740$10,227
SimbrinzaBrinzolamide/Brimonidine Tart52$10,144
CombiganBrimonidine Tartrate/Timolol14$6,392
TyrvayaVarenicline Tartrate12$6,021
Dorzolamide Hcl424$4,565
TobradexTobramycin/Dexamethasone16$4,211
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$4,198
Loteprednol Etabonate36$4,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$549$90,512111 claims
Bausch & Lomb Americas Inc.Xiidra$211$59,39546 claims
Sun Pharmaceutical Industries Inc.Cequa$309$15,43713 claims
Aerie Pharmaceuticals, Inc.Rocklatan$40$11,71121 claims
AlconSimbrinza$58$10,14452 claims
Oyster Point Pharma, Inc.Tyrvaya$291$6,02112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Belleville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →